Shanghai Institute of Materia Medica

Chinese developers of advanced therapeutics, including cell and gene therapies, have continued to garner support from venture capital and private equity investors in the past weeks. Shanghai-based Epi

Mounting concerns over protocol changes and trial design have shrouded Shanghai Junshi Biosciences Co., Ltd. ’s claim of superiority for its COVID-19 oral antiviral VV116 over Pfizer Inc. ’s Paxlovi

Nanjing, China-based Simcere Pharmaceutical Group is weighing multiple development options for its 3CL protease-targeting oral antiviral candidate as potentially the first home-grown contender to P

EU Nod For Paxlovid As Pfizer Hopes To Ramp Up Supply Pfizer Inc. has snagged a conditional marketing authorization (CMA) from the European Commission (EC) for Paxlovid (nirmatrelvir and ritonavir),